Physician

Chelsea Page Houthoofd, M.D.

According to 2025 Medicare claims, Chelsea Houthoofd, M.D. (NPI: 1114308962) practices dermatology in the Midland, MI market, with the plurality of this provider's patient population coming from Midland, MI. This provider's primary affiliated billing organization is JENNIFER NASH, MD DERMATOLOGY ASSOCIATES OF MIDLAND, PLC (NPI: 1629586268; TIN: 824043012) and primary practice location at 48640-6922.

Houthoofd's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 619 traditional Medicare patients, billed 3,325 HCPCS/CPT codes, and received $114,666 in Medicare payments. The top billing code was 99203 (New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more). Part D data shows 1,434 prescription claims across 630 beneficiaries totaling $739,228 in drug costs, led by Dupixent Pen (Dupilumab). Open Payments data shows 50 records totaling $1,038. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $28,352 to $114,666. Similarly, Part D prescription costs have risen steadily, from $861 to $739,228. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$57K$115K2019 Medicare payment: $28,352 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $74,766 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $97,680 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $89,323 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $113,038 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $114,666 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019122703$28,352
20202601,973$74,766
20213772,257$97,680
20224462,314$89,323
20235122,744$113,038
20246193,325$114,666

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$370K$739K2015 Drug cost: $861 (USD; Tot_Drug_Cst)2016 Drug cost: $6,835 (USD; Tot_Drug_Cst)2017 Drug cost: $75,572 (USD; Tot_Drug_Cst)2018 Drug cost: $65,534 (USD; Tot_Drug_Cst)2019 Drug cost: $31,666 (USD; Tot_Drug_Cst)2020 Drug cost: $15,834 (USD; Tot_Drug_Cst)2021 Drug cost: $120,280 (USD; Tot_Drug_Cst)2022 Drug cost: $426,811 (USD; Tot_Drug_Cst)2023 Drug cost: $556,396 (USD; Tot_Drug_Cst)2024 Drug cost: $739,228 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151117$861
201652118$6,835
2017173425$75,572
201897228$65,534
2019127273$31,666
2020212479$15,834
2021345786$120,280
2022381873$426,811
20235261,124$556,396
20246301,434$739,228

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more139139$72
11102Biopsy of related skin growth, first growth194209$60
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more372450$56
17000Destruction of precancer skin growth, 1 growth283336$35
17003Destruction of precancer skin growth, 2-14 growths2551,407$4

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Dupixent PenDupilumab521,344$191,513
OtezlaApremilast22660$97,930
WinleviClascoterone13390$7,164
KetoconazoleKetoconazole28710,310$5,935
Clobetasol PropionateClobetasol Propionate2217,313$5,732

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.50$1,038Janssen Biotech, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Chelsea Page Houthoofd, M.D.?

Tedicare shows public-source Medicare data for Chelsea Page Houthoofd, M.D. (NPI 1114308962), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chelsea Page Houthoofd, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chelsea Page Houthoofd, M.D.?

Chelsea Page Houthoofd, M.D. is linked to JENNIFER NASH, MD DERMATOLOGY ASSOCIATES OF MIDLAND, PLC (billing NPI 1629586268) in the available physician profile data.

Does Chelsea Page Houthoofd, M.D. have Open Payments data?

Chelsea Page Houthoofd, M.D. has 50 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.